Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Neurology

• Publication date

  1999-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1212/WNL.52.6.1239PMID 10214750
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intracellular staining of Mx proteins in cells from peripheral blood, bone marrow and skin.

  1997cited by this paper
• Guidelines for physicians with patients on IFN beta-1b

  1996cited by this paper
• Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers.

  1996cited by this paper
• Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b

  1996cited by this paper
• Interferons, Mx genes, and resistance to influenza virus.

  1995cited by this paper
• Neutralizing interferon beta antibodies in melanoma patients treated with recombinant and natural interferon beta.

  1994cited by this paper
• Pharmacokinetics of recombinant human interferon-beta ser in healthy volunteers and its effect on serum neopterin.

  1993cited by this paper
• Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

  1993cited by this paper
• Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-beta.

  1993cited by this paper
• Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

  1993cited by this paper
• Antibodies that neutralize human beta interferon biologic activity recognize a linear epitope: analysis by synthetic peptide mapping.

  1991cited by this paper
• Effective natural interferon-alpha therapy in recombinant interferon-alpha-resistant patients with hairy cell leukemia.

  1991cited by this paper
• The human intracellular Mx‐homologous protein is specifically induced by type I interferons

  1990cited by this paper
• Analysis of antigenic domains on natural and recombinant human IFN-beta by the inhibition of biologic activities with monoclonal antibodies.

  1989cited by this paper

• A New Serological Autoantibody Signature Associated with Multiple Sclerosis

  2025cites this paper
• The association between blood MxA mRNA and long-term disease activity in early multiple sclerosis

  2022cites this paper
• Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis

  2022cites this paper
• What we know so far about Myxovirus Resistance Protein A (MxA) as a Biomarker of Interferon-Beta Therapy in Patients with Multiple Sclerosis: A systematic Review

  2020influential citation
• Recombinant Interferons Beta-1a and Beta-1b: Protein Structural Features and Problematic Issues with Identity Confirmation

  2018cites this paper
• Molecular insights into the improved clinical performance of PEGylated interferon therapeutics: a molecular dynamics perspective

  2018cites this paper
• COMBINATION THERAPES USING VITAMIN B12 AND INTERFERON FOR TREATMENT OF WIRAL PROLIFERATIVE AND INFLAMMATORY DISESASES

  2017cites this paper
• Cross-reactivity of antibodies against interferon beta in multiple sclerosis patients and interference of the JAK-STAT signaling pathway

  2017cites this paper
• VITAMIN B12 AND INTERFERON FOR TREATMENT OF VIRAL PROLIFERATIVE AND INFLAMMATORY DISEASES

  2017cites this paper
• Personalized Medicine and Theranostics

  2016cites this paper
• Absence of MxA induction is related to a poor clinical response to interferon beta treatment in multiple sclerosis patients

  2016cites this paper
• Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients

  2016cites this paper
• A gene expression study denies the ability of 25 candidate biomarkers to predict the interferon-beta treatment response in multiple sclerosis patients.

  2016cites this paper
• Pharmacokinetic considerations in the treatment of multiple sclerosis with interferon-β

  2015cites this paper
• Peripheral blood biomarkers in multiple sclerosis.

  2015cites this paper
• Evaluation of the impact of neutralizing antibodies on IFNβ response.

  2015cites this paper
• Pharmacogenomics of interferon-β in multiple sclerosis: what has been accomplished and how can we ensure future progress?

  2015cites this paper
• Biological monitoring of IFN-β therapy in Multiple Sclerosis.

  2015influential citation
• Body fluid biomarkers in multiple sclerosis.

  2014cites this paper
• A modified immune tolerant mouse model to study the immunogenicity of recombinant human interferon beta.

  2014cites this paper
• Anti-Interferon Beta Antibody Titers Strongly Correlate Between Two Bioassays and In Vivo Biomarker Expression, and Indicates That a Titer of 150 TRU/mL Is a Biologically Functional Cut-Point

  2014cites this paper
• Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group

  2014cites this paper
• Chapter 2 . 1 Reduced biological activity of recombinant IFN-β and treatment response IFN-β bioactivity measurement in MS : feasibility for routine clinical practice

  2014cites this paper
• Identifying responders and nonresponders to interferon therapy in multiple sclerosis

  2014cites this paper
• Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development

  2014cites this paper
• Search of prognostic biomarkers in patients with multiple sclerosis

  2014cites this paper
• High-dose intravenous interferon-beta in multiple sclerosis patients with high-titer neutralizing antibodies (HINABS II) - A pilot study.

  2014cites this paper
• A novel cell-based assay for measuring neutralizing autoantibodies against type I interferons in patients with autoimmune polyendocrine syndrome type 1.

  2014cites this paper
• Antibodies against interferon-beta in neuromyelitis optica patients.

  2014cites this paper
• Ein Paradigmenwechsel und die Zukunft

  2013cites this paper
• ANTI-DRUG ANTIBODIES IN PATIENTS WITH MULTIPLE SCLEROSIS

  2013cites this paper
• Sledování biologické účinnosti interferonu-β při léčbě pacientů s roztroušenou sklerózou v České republice

  2013cites this paper
• Pharmakologie von Interferon beta-1b

  2013cites this paper
• Result in an In Vivo Response Directed at the Does Not β Cell Epitope in Human IFN- T + Elimination of an Immunodominant CD4

  2013cites this paper
• Effect of Treatment Regimen on the Immunogenicity of Human Interferon Beta in Immune Tolerant Mice

  2013cites this paper
• Understanding drug resistance to biologic therapy Development of resistance to biologic therapies with reference to IFN-b

  2012cites this paper
• Comparison of three PCR assays for the evaluation of interferon-β biological activity in patients with multiple sclerosis

  2012cites this paper
• Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial

  2012cites this paper
• Persistency of neutralizing antibodies depends on titer and interferon-beta preparation

  2012cites this paper
• MxA Gene Expression Analysis as an Interferon-β Bioactivity Measurement in Patients with Multiple Sclerosis and the Identification of Antibody-Mediated Decreased Bioactivity

  2012cites this paper
• Disease Biomarkers in Multiple Sclerosis

  2012cites this paper
• Development of resistance to biologic therapies with reference to IFN-β.

  2012cites this paper
• Determinants of interferon β efficacy in patients with multiple sclerosis

  2011cites this paper
• Assessment of the sensitivity of anti-interferon binding and neutralizing antibody assays in patients with relapsing -remitting multiple sclerosis under interferon- beta treatment- A comparative study

  2011cites this paper
• Pharmacogenomics and Multiple Sclerosis: Moving Toward Individualized Medicine

  2011cites this paper
• Search for Specific Biomarkers of IFNβ Bioactivity in Patients with Multiple Sclerosis

  2011cites this paper
• The Use of Pharmacodynamics as a Surrogate Marker for the Detection of Anti‐Drug Neutralizing Antibodies

  2011cites this paper
• One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients

  2011cites this paper
• Interferon β-1b–neutralizing antibodies 5 years after clinically isolated syndrome

  2011cites this paper
• Interferon β-1b directly modulates human neural stem/progenitor cell fate.

  2011cites this paper
• Detection of Neutralizing Antibodies against Interferon Beta by Real‐Time RT‐PCR

  2011cites this paper
• Assessment of the sensitivity of anti-interferon binding and neutralizing antibody assays in patients with relapsing-remitting multiple sclerosis under interferon-beta treatment-A comparative study

  2011cites this paper
• Interferon beta treatment: Bioavailability and antiviral activity in multiple sclerosis patients

  2011cites this paper
• Beta-interferon for multiple sclerosis.

  2011cites this paper
• Role of Differential Expression of Interferon Receptor Isoforms on the Response of Multiple Sclerosis Patients to Therapy with Interferon Beta

  2010cites this paper
• Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon beta.

  2010cites this paper
• Neutralizing antibodies and the biological response to interferon-beta therapy

  2010cites this paper
• Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.

  2010cites this paper
• Polymorphisms of innate pattern recognition receptors, response to interferon-beta and development of neutralizing antibodies in multiple sclerosis patients

  2010cites this paper
• Chapter 6 - Biomarkers in Multiple Sclerosis

  2010cites this paper
• Use of Anti‐Interferon Beta Antibody Measurements in Multiple Sclerosis

  2010cites this paper
• of neutralizing antibodies in multiple sclerosis patients Polymorphisms of innate pattern recognition receptors , response to interferon-beta and development

  2010cites this paper
• Effect of anti-IFNβ antibodies on MRI lesions of MS patients in the BECOME study

  2009cites this paper
• Identification of new sensitive biomarkers for the in vivo response to interferon‐β treatment in multiple sclerosis using DNA‐array evaluation

  2009cites this paper
• The Neutralization of Interferons by Antibody III. The Constant Antibody Bioassay, A Highly Sensitive Quantitative Detector of Low Antibody Levels

  2009cites this paper
• Neutralizing antibodies in multiple sclerosis patients treated with 375 μg interferon-β-1b

  2009cites this paper
• Effect of neutralizing antibodies on biomarker responses to interferon beta

  2009cites this paper
• Neutralizing Antibodies to Interferon-β and other Immunological Treatments for Multiple Sclerosis

  2009cites this paper
• Interferon-β bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice

  2009cites this paper
• Absence of MxA induction by interferon β in patients with MS reflects complete loss of bioactivity

  2009cites this paper
• High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study

  2009cites this paper
• Lack of interferon‐beta bioactivity is associated with the occurrence of relapses in multiple sclerosis

  2009cites this paper
• Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making.

  2009cites this paper
• Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis

  2009cites this paper
• Neutralizing antibodies explain the poor clinical response to Interferon beta in a small proportion of patients with Multiple Sclerosis: a retrospective study

  2009cites this paper
• Neutralizing antibodies in multiple sclerosis patients treated with 375 micrograms interferon-beta-1b.

  2009cites this paper
• Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon‐β

  2009cites this paper
• Expression and regulation of IFN / receptor in IFN -treated patients with multiple sclerosis

  2008cites this paper
• 2 Clinical Aspects of Immunogenicity to Biopharmaceuticals

  2008cites this paper
• Development of a bioassay for quantification of neutralising antibodies against human interferon-beta in mouse sera.

  2008cites this paper
• Review: Neutralizing antibodies against interferon-beta

  2008influential citation
• The implications of immunogenicity for protein-based multiple sclerosis therapies.

  2008cites this paper
• BAFF is a Biological Response Marker to IFN-β Treatment in Multiple Sclerosis

  2008cites this paper
• Predictive markers for response to interferon therapy in patients with multiple sclerosis

  2008cites this paper
• MxA protein – an interferon beta biomarker in primary progressive multiple sclerosis patients

  2008cites this paper
• MxA protein assay for optimal monitoring of IFN‐β bioactivity in the treatment of MS patients

  2008cites this paper
• Management of neutralizing antibodies against beta-IFN in beta-IFN-treated multiple sclerosis patients

  2008cites this paper
• ΠΑΝΕΠΙΣΤΗΜΙΟ ΠΑΤΡΩΝ

  2008cites this paper
• Neutralizing and Binding Antibodies to Interferon Beta in Patients with Multiple Sclerosis: A Comparison of Assay Results from Three Italian Centres

  2008cites this paper
• Biological Markers of Prognostic Value in Multiple Sclerosis

  2008cites this paper
• Interferon-beta treatment in multiple sclerosis : Analysis of neutralizing antibodies

  2008influential citation
• Is the treatment effect of IFN-β restored after the disappearance of neutralizing antibodies?

  2008cites this paper
• Neutralizing antibodies against interferon-Beta.

  2008cites this paper
• Clinical Aspects of Immunogenicity to Biopharmaceuticals

  2008cites this paper
• Comparative study of four different assays for the detection of binding antibodies against interferon-β

  2008cites this paper
• Die Therapie der Multiplen Sklerose mit IFN-β induziert den

  2008cites this paper
• Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis

  2007cites this paper
• The IgG subclass-specificities of anti-IFNbeta antibodies change with time and differ between the IFNbeta products in relapsing remitting multiple sclerosis patients.

  2007cites this paper
• Anti-interferon-β neutralising activity is not entirely mediated by antibodies

  2007cites this paper
• In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent

  2007cites this paper